A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.
Clin Cancer Res
; 26(2): 344-353, 2020 01 15.
Article
in En
| MEDLINE
| ID: mdl-31672767
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Receptors, CXCR4
/
Multiple Myeloma
Type of study:
Clinical_trials
Limits:
Aged
/
Humans
/
Middle aged
Language:
En
Journal:
Clin Cancer Res
Journal subject:
NEOPLASIAS
Year:
2020
Type:
Article